Ucsf Aids Research Institute San Francisco, CA - 94105

Ucsf Aids Research Institute is categorized under Medical Research in San Francisco, CA and active since 2012.

Ucsf Aids Research Institute was established in 2012, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 541720 by the NAICS.

If you are seeking more information, feel free to contact Susan Kegeles at the company’s single location by writing to 50 Beale St # 1300, San Francisco, California CA 94105 or by phoning (415) 597-9100. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Ucsf Aids Research Institute
Contact Person: Susan Kegeles
Address: 50 Beale St # 1300, San Francisco, California 94105
Phone Number: (415) 597-9100
Website Address: caps.ucsf.edu
Annual Revenue (USD): $50.000 to $99.999
Founded: 2012
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Medical Research
SIC Code: 8733
NAICS Code: 541720
Share This Business:

Ucsf Aids Research Institute was started in 2012 to provide professional Medical Research under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.

Feel free to contact Susan Kegeles for inquiries that concern Ucsf Aids Research Institute by calling the company number (415) 597-9100, as your correspondence is most welcome. Additionally, the physical location of the single location of Ucsf Aids Research Institute can be found at the coordinates 37.791774,-122.396763 as well as the street address 50 Beale St # 1300 in San Francisco, California 94105.

For its online presence, you may visit Ucsf Aids Research Institute’s website at caps.ucsf.edu and engage with its social media outlets through on Twitter and on Facebook.